organization · Reporting owner
V-Co Investors 3 LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vivos Therapeutics, Inc.VVOS · Entity 8396 | 10% owner | March 31, 2026 | April 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vivos Therapeutics, Inc.
Report date March 31, 2026 · Filed April 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,353,625 |
Reported balance
Holding disclosure · report date 2026-03-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,353,625 |
| Pre-Funded WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-31 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Pre-Funded Warrant has a term ending on the complete exercise of the Pre-Funded Warrant. |
| Series A Common Stock WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2028-03-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-31 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed |
| Series B Common Stock WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2031-03-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-31 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed |
Filing footnotes · ownership attribution and instrument terms
F1: The Pre-Funded Warrant has a term ending on the complete exercise of the Pre-Funded Warrant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 2, 2026 23:34 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseSeries B Common Stock Warrant · Derivative | 1,783,582 | $1.34 Strike: $1.09 | $2,389,999.88 |
DisclosureSEC source: 0002074003-26-000008 · ownership.xml · derivative · entry 5 Skaff Michael C · CIK 0002074003 · 10% owner V-Co Investors 3 LLC · CIK 0002114460 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By V-Co Investors 3 LLC Disclosed balance after: 1,783,582 Underlying: Common Stock · 1,783,582 shares Expires 2031-03-31 F2 · ownership.nature: Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 23:34 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseSeries A Common Stock Warrant · Derivative | 1,783,582 | $1.34 Strike: $1.09 | $2,389,999.88 |
DisclosureSEC source: 0002074003-26-000008 · ownership.xml · derivative · entry 4 Skaff Michael C · CIK 0002074003 · 10% owner V-Co Investors 3 LLC · CIK 0002114460 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By V-CO Investors 3 LLC Disclosed balance after: 1,783,582 Underlying: Common Stock · 1,783,582 shares Expires 2028-03-31 F2 · ownership.nature: Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 23:34 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchasePre-Funded Warrant · Derivative | 429,957 | $1.34 Strike: $0.00 | $576,142.38 |
DisclosureSEC source: 0002074003-26-000008 · ownership.xml · derivative · entry 3 Skaff Michael C · CIK 0002074003 · 10% owner V-Co Investors 3 LLC · CIK 0002114460 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By V-CO Investors 3 LLC Disclosed balance after: 429,957 Underlying: Common Stock · 429,957 shares Expires not disclosed F3 · derivative.expiration_date: The Pre-Funded Warrant has a term ending on the complete exercise of the Pre-Funded Warrant. F2 · ownership.nature: Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 23:34 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 308,848 | $1.34 | $413,856.32 |
DisclosureSEC source: 0002074003-26-000008 · ownership.xml · nonDerivative · entry 2 Skaff Michael C · CIK 0002074003 · 10% owner V-Co Investors 3 LLC · CIK 0002114460 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By V-CO Investors 3 LLC Disclosed balance after: 1,353,625 F2 · ownership.nature: Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 23:34 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 1,044,777 | $1.34 | $1,400,001.18 |
DisclosureSEC source: 0002074003-26-000008 · ownership.xml · nonDerivative · entry 1 Skaff Michael C · CIK 0002074003 · 10% owner V-Co Investors 3 LLC · CIK 0002114460 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By V-CO Investors 3 LLC Disclosed balance after: 1,044,777 F1 · shares: On March 31, 2026, V-Co Investors 3, LLC converted a bridge promissory note in the amount of $1,400,000 entered into between the reporting person and the Issuer into shares of the Issuer's common stock, based on $1.09 per share of Common Stock plus $0.25 per share in accordance with the Nasdaq minimum price rules. F2 · ownership.nature: Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.